尽管顺铂作为癌症治疗的基石有着悠久的历史，但获得性化疗耐药性和对健康组织的显着影响限制了其使用。肝毒性是其副作用之一。辅助疗法不仅可以减轻顺铂引起的肝损伤，还可以提高化疗的疗效。在此背景下，合成了一种新型季铵壳聚糖席夫碱（QACSB），并将其作为包封剂用于原位合成QACSB-ZnO纳米复合材料。将30只雄性白化大鼠分为1组（对照）蒸馏水组、1组2组（顺铂治疗）（12mg/kg，腹腔注射）和第3组（QACSB-ZnO NCs/顺铂治疗）（150mg/kg/天QACSB-ZnO NCs，腹腔注射）单剂量顺铂14天。测量肝功能、组织 TNF-α、MDA 和 GSH，并进行组织病理学和免疫组织化学研究。QACSB-ZnO NC 显着恢复肝功能、组织 TNF-α、MDA 和 GSH 水平 (p<0.001)。组织病理学检查显示顺铂治疗组与其他组相比出现片状坏死。与 CP 组相比，QACSB-ZnO NC 表现出较弱的 TGF-β1（评分 = 4）和中等的 Bcl-2 免疫组织化学表达（评分 = 6）。QACSB-ZnO NC 已被证明可以保护肝脏免受顺铂诱导的肝毒性.版权所有 © 2024。由 Elsevier B.V. 出版

Despite cisplatin's long history as a cornerstone in cancer therapy, both acquired chemoresistance and significant impacts on healthy tissues limit its use. Hepatotoxicity is one of its side effects. Adjunct therapies have shown promise in not only attenuating liver damage caused by cisplatin but also in enhancing the efficacy of chemotherapy. In this context, a new quaternary ammonium chitosan Schiff base (QACSB) was synthesized and applied as an encapsulating agent for the in-situ synthesis of QACSB-ZnO nanocomposite.Thirty male albino rats were classified into Group 1 (control) distilled water, Group 2 (Cisplatin-treated) (12 mg/kg, i.p), and Group 3 (QACSB-ZnO NCs/cisplatin-treated) (150 mg/kg/day QACSB-ZnO NCs, i.p) for 14 days + a single dose of cisplatin. Liver functions, tissue TNF-α, MDA, and GSH were measured as well as histopathological and immunohistochemical studies were performed.The QACSB-ZnO NCs significantly restore liver functions, tissue TNF-α, MDA, and GSH levels (p < 0.001). Histopathological examination showed patchy necrosis in the cisplatin-treated group versus other groups. The QACSB-ZnO NCs showed a weak TGF-β1 (score = 4) and a moderate Bcl-2 immunohistochemistry expression (score = 6) versus the CP group.QACSB-ZnO NCs have been shown to protect the liver from cisplatin-induced hepatotoxicity.Copyright © 2024. Published by Elsevier B.V.